Management of hypogonadism from birth to adolescence.

@article{Howard2018ManagementOH,
  title={Management of hypogonadism from birth to adolescence.},
  author={Sasha R. Howard and Leo Dunkel},
  journal={Best practice \& research. Clinical endocrinology \& metabolism},
  year={2018},
  volume={32 4},
  pages={
          355-372
        }
}
  • S. HowardL. Dunkel
  • Published 1 August 2018
  • Medicine
  • Best practice & research. Clinical endocrinology & metabolism

Congenital Hypogonadotrophic Hypogonadism: Minipuberty and the Case for Neonatal Diagnosis

The clinical implications of missing minipuberty in CHH and therapeutic strategies that can modify the course of disease are reviewed, as well as a targeted approach to identifying affected male infants by integrating clinical and biochemical data in the early postnatal months are explored.

Hypogonadism in male infants and adolescents: new androgen formulations.

This special issue is aimed to illustrate new T formulations and their potential role as replacement therapy in the pediatric population, as well as to highlight investigational areas to contribute to health care improvement in these patients.

Psychological Aspects of Congenital Hypogonadotropic Hypogonadism

An approach to comprehensive care that spans medical management as well as appropriate attention, care and referrals to peer-to-peer support and mental health services to ameliorate the psychological aspects of CHH/KS is outlined.

Male hypogonadotropic hypogonadism in various genetic disorders

Most of the inborn diseases that involve hypogonadotropic hypogOnadism as one of their components are reviewed to review.

Primary gonadal failure.

Interpretation of reproductive hormones before, during and after the pubertal transition—Identifying health and disordered puberty

  • S. Howard
  • Medicine, Biology
    Clinical endocrinology
  • 2021
This review is focused on the description of the endocrine axes in healthy puberty and the markers of disorders of puberty that can aid diagnosis and management for patients with these conditions.

45,X/46,X,i(Yp): Importance of Assessment and Support during Puberty and Adolescence

This patient presented with a pubertal course suggestive of a delayed puberty with gynecomastia, reduced growth rate, and infertility that need testosterone treatment to induce the appearance of the secondary sex characteristics and emphasizes the importance of appropriate management of puberty in people with 45,X/46,X,i(Yp.

The impact of male factors and their correct and early diagnosis in the infertile couple's pathway: 2021 perspectives

A comprehensive overview of the multifaceted role of the andrologist in the study of male factor infertility is provided, which indicates that a careful medical history and physical examination, followed by semen analysis, always represent the basic starting points of the diagnostic work up in male partner of an infertile couple.

Leydig Cells in the Adult Testis: Characterization, Regulation and Potential Applications.

Androgen deficiency (hypogonadism) affects males of all ages. Testosterone replacement therapy (TRT) is effective in restoring serum testosterone and relieving symptoms. TRT, however, is reported to

References

SHOWING 1-10 OF 107 REFERENCES

What is the optimal therapy for young males with hypogonadotropic hypogonadism?

Treatment is likely to be life‐long, requiring regular monitoring for its optimization and avoidance of adverse responses, and ‘Reversible genetic hypogonadotropic hypogOnadism’ is a recently described entity which has implications for the long‐term management of patients with HH.

Long-term outcome of idiopathic hypogonadotropic hypogonadism

The demonstration of reversibility, the impact of inadequate testosterone replacement and the good response to induction of spermatogenesis confirm the need for specialist care and long-term follow-up in men with idiopathic hypogonadotropic hypogONadism.

Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropins replacement therapy protocols

  • N. SatoT. Hasegawa Toshiaki Tanaka
  • Medicine, Biology
    Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
  • 2015
This study investigates the current situation of treatment for children with MHH in Japan and proposes a new HRT protocol using preemptive FSH therapy prior to GRT aimed at achieving future fertility in patients with congenital MHH.

Reversal and relapse of hypogonadotropic hypogonadism: resilience and fragility of the reproductive neuroendocrine system.

Reversal of IHH may be more widespread than previously appreciated and occurs across a broad range of genotypes and phenotypes, and enrichment for mutations affecting neurokinin B signaling in patients who reversed indicates that this signaling pathway for normal pubertal timing is dispensable later in life.

Management of Puberty in Constitutional Delay of Growth and Puberty

Compared with other regimens, short-course low-dose depot T i.m.o. is an effective, practical, safe, well tolerated, and inexpensive regimen for management of puberty in boys with CDGP.

Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism

Encouraging results of neonatal therapy, together with a few reports of prepubertal treatment, support the use of this novel therapeutic strategy aimed at improving sexual and reproductive functions in adulthood in male patients with CHH.

Constitutional Delayed Puberty in Males and Hypogonadotropic Hypogonadism: A Reliable and Cost Effective Approach to Differential Diagnosis

The data confirm that a basal serum T 50 ng/dl is evidence of the onset of puberty and suggest that a single injection of HCG 15 IU/kg, with serum T determined 48 hours later, is more discriminatory and offers the most reliable, easy to perform, least painful, and by far the most cost effective test to differentiate CDP from HH.

Early postnatal treatment of hypogonadotropic hypogonadism with recombinant human FSH and LH.

Gonadotropin treatment in an infant with hypog onadotropic hypogonadism succeeded in inducing an increase in inhibin B and testicular growth.

Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome.

BACKGROUND Boys with prepubertal onset of hypogonadotropic hypogonadism (HH) are at a risk of poor testis growth and impaired spermatogenesis. One potential cause for this is deficient proliferation

Congenital hypogonadotropic hypogonadism, functional hypogonadotropism or constitutional delay of growth and puberty? An analysis of a large patient series from a single tertiary center

In prepubertal boys, testicular size appeared as effective as INHB and GnRH-induced LH levels in the differential diagnosis between CHH and CDGP, whereas markers of similar value could not be identified in girls.
...